Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation: early-phase trial registry
1 of 2 indexed Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation: 2 US clinical trials tracked, 1 recruiting.
Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Emory University, running 1 of these trials.
Enrollment posture brief
Registry condition infiltrating-bladder-urothelial-carcinoma-with-squamous-differentiation
OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Emory University
NCT04878029
Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer
M.D. Anderson Cancer Center
NCT03744793
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Emory University sponsors the most Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation trials on record, review their full trial history before evaluating a specific study. See Emory University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation condition card totals 2 registered trials; most-linked intervention Avelumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.